U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07936032) titled 'Phase I Study to Evaluate Single and Multiple Oral Doses of HW281171 Tablets in Healthy Participants' on Nov. 05.
Brief Summary: This phase 1 study aims to evaluate the safety, tolerability and pharmacokinetic profiles of HW281171 in healthy Participants. The study consists of three parts: Part A (Single-Dose Escalation Study), Part B (Food Effect and Metabolite Study), and Part C (Multiple-Dose Escalation Study).
Study Start Date: Nov. 18
Study Type: INTERVENTIONAL
Condition:
Chronic Urticaria
Intervention:
DRUG: HW281171 tablets
Administered orally daily at pre-specified dose and frequency.
DRUG: Placebo tablets
Administe...